B+
Bull case
25%
Probability
Target price
$21.25
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
FTRE
FortreaCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Raised FY2026 guidance, positive book-to-bill, large backlog, and improved adjusted EBITDA and adjusted EPS support a constructive execution case [#SEC-8K-2026-07-29].
Posture
Mixed
Lead driver
Value
What changed
1 setup hits (3d) with net bullish as of 2026-10-24.
What can break
Backlog conversion, demand durability, margins, and cash-flow execution remain key monitoring points.
Momentum
98
Value
60
Sentiment
31
Setup hits (3d)
1 · Net Bullish
AI TargetsBase $18.53 · Bull $21.25 · Bear $14.80Analysis 2026-08-17; returns require an exact persisted reference.
Earnings
2026-10-29 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-17 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $22.45
Why
Momentum98 · Δ7d +1.8
Value60 · Δ7d -0.3
Sentiment31 · Δ7d -3.1
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Confirming evidence
- • 1 setup hits (3d) with net bullish as of 2026-10-24.
- • Next scheduled catalyst: earnings 2026-10-29 · BMO.
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • Backlog conversion, demand durability, margins, and cash-flow execution remain key monitoring points.
- • Ongoing CFO leadership uncertainty may weigh on execution confidence.
- • Revenue remains below the prior-year quarter, CFO availability is uncertain, and recent open-market insider sales add confidence risk [#PR-EARNINGS-2026-08-08] [#SEC-FORM4-2026-08-07].
Catalyst clock
2026-10-29 · BMO
Q2 execution and raised FY2026 guidance
Lead driver: Value · See fundamentals
Momentum
98
8% active weight
Current posture
7d trendFlat
Δ7d
+1.8
Δ21d
+11.0
Value
60
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-1.2
Sentiment
31
45% active weight
Current posture
7d trendSoftening
Δ7d
-3.1
Δ21d
-22.6
Why this grade
Composite grade C. Momentum 97.5 / Value 60.2 / Sentiment 31.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-17. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$18.53
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$14.80
Analysis reference price unavailable
Analysis 2026-08-17 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$2.25B
Beta
-
Shares Out
95.1M
P/E (TTM) · Derived
-2.2
P/S (TTM)
0.56
P/FCF (TTM)
6.47
Rev YoY
-4.5%
EPS YoY
-96.6%
Gross Margin
+16.4%
Op Margin
+1.0%
Net Debt
$941.4M
Current Ratio
0.96
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data